|
|
Long-term outcome of oligodendrogliomas
C. Lebrun, MD,
D. Fontaine, MD, A. Ramaioli, PhD, F.
Vandenbos, MD, S. Chanalet, MD, M. Lonjon,
MD PhD, J. F. Michiels, MD PhD, V. Bourg, MD,
P. Paquis, MD PhD, M. Chatel, MD, M.
Frenay, MD and The Nice Brain Tumor Study Group
From the Departments of Neurology
(Drs. Lebrun, Bourg, and Chatel), Neurosurgery (Drs. Fontaine, Lonjon,
and Paquis), Antoine Lacassagne Center (Drs. Ramaioli and Frenay),
Anatomo-pathology (Drs. Vandenbos and Michiels), and Radiology (Dr.
Chanalet), Hôpital Pasteur, Nice, France. Address correspondence and
reprint requests to Dr. Lebrun, Service de Neurologie, Hôpital
Pasteur, 30 voie romaine, BP 69, 06002 Nice, France; e-mail:
christine.lebrun-frenay@wanadoo.fr. Received September 29, 2003.
Accepted in final form January 13, 2004.
Background.
Favorable prognostic factors for oligodendroglial tumors
include age younger than 40 years, low tumor grade, and extent
of resection.
Objective. To assess
survival time and prognostic factors of 100 patients with
oligodendrogliomas diagnosed between 1995 and 2002.
Methods. The tumors were
rated histologically by the WHO classification as low grade
(grade II) or anaplastic (grade III).
One hundred patients were categorized into three groups:
group A: grade II, group B: secondary grade III (low grade
with anaplastic transformation during the follow-up), group
C: de novo grade III.
All patients were symptomatic at presentation and underwent neurosurgical
procedure for histologic diagnosis.
Follow-up was performed with clinical assessment, brain
MRI, and MIBI scintigraphy.
Results. There were 66
men and 34 women (mean age at diagnosis 46.7 years).
The most common first symptom was partial epileptic seizure
(75%).
Fifty-six patients had initial gadolinium enhancement (A:
15.6%; B: 36.8% as grade II, 95% as grade III; C: 90%), generally
associated with MIBI hypermetabolism (p < 0.0001).
Survival rates at 2, 5, and 10 years were A: 88%, 88%, 85%; B:
79%, 64%, 42%; C: 43%, 16%, 15%.
Conclusions. Secondary
anaplastic oligodendroglioma patients were younger than
patients with de novo anaplastic oligodendrogliomas.
Histologic confirmation is mandatory because some low grade oligodendrogliomas
had gadolinium enhancement on MRI and some anaplastic did
not.
Survival time was longer for secondary than for de novo
anaplastic oligodendrogliomas without difference in the
duration of the malignant phase of the disease.
© 2004 American Academy of
Neurology
|
